RESOURCES
FOR HEALTHCARE PROVIDERS AND PATIENTS
Comprehensive support
from the start
Hizentra Connect is a suite of support programs and resources to optimize your patient’s experience and provide ongoing support throughout their journey
To get the guidance and support you need:
Call 1-877-355-4447 Monday-Friday, 8 AM to 8 PM ET.
Healthcare Provider Resources
Helpful materials for you and your staff
Access important tools to help you and your office start and keep patients on therapy.
PATIENT Resources
Tools to help your patients
Video Library
Administration videos
How to Self-Infuse Hizentra
This video will take patients step by step through the self-infusion process.
Preparation: Vials vs Prefilled Syringes
See the simplicity of prefilled syringes vs vials.
Real patient experiences
Arthur
Arthur shares how self-infusing with Hizentra prefilled syringes provides consistent Ig levels, which help him maintain a steady level of strength and energy.
Stephanie
Stephanie talks about avoiding the ups and downs of IVIg by moving to Hizentra and how she maintains the mobility she needs to manage daily tasks and activities.
Patti
Patti celebrates the empowerment and freedom she enjoys after moving to Hizentra prefilled syringes.
Appolos
Appolos explains changing from finding a vein to finding freedom with Hizentra.
Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; Ig, immunoglobulin; IVIg, intravenous immunoglobulin; PI, primary immunodeficiency; SCIg, subcutaneous immunoglobulin.
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.